{"id":"NCT01660256","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Confirmatory Study of OPC-12759 Ophthalmic Solution","officialTitle":"Confirmatory Study of OPC-12759 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2013-03","completion":"2013-05","firstPosted":"2012-08-08","resultsPosted":"2021-05-05","lastUpdate":"2021-05-05"},"enrollment":209,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"OPC-12759","otherNames":["rebamipide"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OPC-12759 ophthalmic solution","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"OPC-12759 ophthalmic suspension","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to verify whether OPC-12759 ophthalmic solution is effective compared with placebo in dry eye patients. OPC-12759 ophthalmic suspension will be used as a reference drug.","primaryOutcome":{"measure":"Change in Fluorescein Corneal Staining (FCS) Score From Baseline","timeFrame":"Baseline, Week 4","effectByArm":[{"arm":"OPC-12759 Solution","deltaMin":-3.3,"sd":0.2},{"arm":"Placebo","deltaMin":-2,"sd":0.3},{"arm":"OPC-12759 Suspension","deltaMin":-2.9,"sd":0.3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":84},"commonTop":["Dysgeusia","Nasopharyngitis","Abnormal sensation in eye","Eye irritation","Ocular discomfort"]}}